FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder


The FDA has approved Takeda Pharmaceutical Co Ltd's TAK Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in Type 3 von Willebrand disease (VWD) receiving on-demand therapy.

  • Vonvendi is the only recombinant von Willebrand factor (VWF) replacement therapy and the first and only treatment to reduce the frequency of bleeding episodes for severe Type 3 VWD approved by the FDA for routine prophylactic use. 
  • Related content: Benzinga's Full FDA Calendar.
  • Vonvendi is now indicated for routine prophylaxis in adults with severe Type 3 VWD receiving on-demand therapy and on-demand and perioperative bleed management in adults with VWD.
  • VWD is an inherited disorder caused by a deficiency or impaired function of VWF, one of several types of proteins in the blood that are needed for proper blood clotting.
  • Vonvendi is an infused product specifically designed to replace the body's missing or dysfunctional VWF.
  • The approval is based on a prospective, open-label, international multicenter study. 
  • The median annualized bleeding rates (ABR) for all bleeds was reduced from historical median ABR 5.0 to an on-study median ABR of 2.3, equivalent to a 54.7% reduction. 
  • Price Action: TAK shares are up 0.10% at $14.41 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!